Compare Modine Manufacturing Company (MOD) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Modine Manufacturing Company vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Modine Manufacturing Company trades at $156.29 (market cap $9.17B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Modine Manufacturing Company is far larger — about 9.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Modine Manufacturing Company nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Modine Manufacturing Company for 33 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| MOD | MRVI | |
|---|---|---|
Market Cap | $9.17B | $972.90M |
Volume | 1,397,357 | 4,325,710 |
Sector | Industrials | Health |
52-Week High | $283.95 | $9.00 |
52-Week Low | $110.73 | $2.83 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $9.60B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Modine Manufacturing (MOD) trades at $172.57, showing minimal daily change. The stock exhibits a bearish technical signal with strong selling pressure on moving averages, though oscillators are neutral. Fundamentally, the company reported revenue of $2.58 billion in 2025 with a net income of $184 million, but profit margins are expected to compress in 2026. Recent corporate actions include the completion of a $946 million spin-off of its Performance Technologies unit with Gentherm, marking a strategic shift.
The outlook is mixed: strong analyst consensus with a $331.25 price target suggests significant upside, but near-term risks include margin pressure and bearish technical trends. Investment opportunity hinges on successful execution post-spin-off and data center cooling growth, while volatility from restructuring and market sentiment poses risks.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
